{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:11:10Z","timestamp":1791155470499,"version":"4.1.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,11,30]],"date-time":"2011-11-30T00:00:00Z","timestamp":1322611200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s00262-011-1150-z","type":"journal-article","created":{"date-parts":[[2011,11,30]],"date-time":"2011-11-30T04:32:34Z","timestamp":1322627554000},"page":"991-1003","source":"Crossref","is-referenced-by-count":37,"title":["Targeting HER2\/neu with a fully human IgE to harness the allergic reaction against cancer cells"],"prefix":"10.1007","volume":"61","author":[{"given":"Tracy R.","family":"Daniels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Leuchter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela","family":"Quintero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Helguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otoniel","family":"Mart\u00ednez-Maza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit C.","family":"Schultes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher F.","family":"Nicodemus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel L.","family":"Penichet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,11,30]]},"reference":[{"key":"1150_CR1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics 2010. CA Cancer J Clin 60:277\u2013300","journal-title":"CA Cancer J Clin"},{"key":"1150_CR2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235:177\u2013182","journal-title":"Science"},{"key":"1150_CR3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2010.04.009","volume":"146","author":"W Tai","year":"2010","unstructured":"Tai W, Mahato R, Cheng K (2010) The role of HER2 in cancer therapy and targeted drug delivery. J Control Releas 146:264\u2013275","journal-title":"J Control Releas"},{"key":"1150_CR4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al (1989) Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244:707\u2013712","journal-title":"Science"},{"key":"1150_CR5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00004347-199401000-00006","volume":"13","author":"H Meden","year":"1994","unstructured":"Meden H, Marx D, Rath W, Kron M, Fattahi-Meibodi A, Hinney B, Kuhn W, Schauer A (1994) Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 13:45\u201353","journal-title":"Int J Gynecol Pathol"},{"key":"1150_CR6","first-page":"4087","volume":"50","author":"A Berchuck","year":"1990","unstructured":"Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P et al (1990) Overexpression of HER-2\/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50:4087\u20134091","journal-title":"Cancer Res"},{"key":"1150_CR7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","volume":"5","author":"NE Hynes","year":"2005","unstructured":"Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341\u2013354","journal-title":"Nat Rev Cancer"},{"key":"1150_CR8","doi-asserted-by":"crossref","unstructured":"Ahn ER, Vogel CL (2011) Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat [Epub ahead of print]","DOI":"10.1007\/s10549-011-1781-y"},{"key":"1150_CR9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/187569209790112337","volume":"7","author":"R Nahta","year":"2009","unstructured":"Nahta R, Shabaya S, Ozbay T, Rowe DL (2009) Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens. Curr Pharmacogenomics Pers Med 7:263\u2013274","journal-title":"Curr Pharmacogenomics Pers Med"},{"key":"1150_CR10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ctrv.2009.10.001","volume":"36","author":"Y Fernandez","year":"2010","unstructured":"Fernandez Y, Cueva J, Palomo AG, Ramos M, de Juan A, Calvo L, Garcia-Mata J, Garcia-Teijido P, Pelaez I, Garcia-Estevez L (2010) Novel therapeutic approaches to the treatment of metastatic breast cancer. Cancer Treat Rev 36:33\u201342","journal-title":"Cancer Treat Rev"},{"key":"1150_CR11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","volume":"21","author":"MA Bookman","year":"2003","unstructured":"Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group. J Clin Oncol 21:283\u2013290","journal-title":"J Clin Oncol"},{"key":"1150_CR12","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1398-9995.2008.01768.x","volume":"63","author":"E Jensen-Jarolim","year":"2008","unstructured":"Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, Penichet ML, Rodriguez JA, Siccardi AG, Vangelista L, Riemer AB, Gould H (2008) AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy 63:1255\u20131266","journal-title":"Allergy"},{"key":"1150_CR13","doi-asserted-by":"crossref","unstructured":"Daniels TR, Rodriguez JA, Ortiz-Sanchez, Helguera G, Penichet ML (2010) The IgE antibody and its use in cancer immunotherapy. In: Penichet ML, Jensen-Jarolim E (eds) Cancer and IgE: introducing the concept of allergooncology. New York, Springer, pp 159\u2013184","DOI":"10.1007\/978-1-60761-451-7_7"},{"key":"1150_CR14","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1146\/annurev.immunol.17.1.931","volume":"17","author":"JP Kinet","year":"1999","unstructured":"Kinet JP (1999) The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. Annu Rev Immunol 17:931\u2013972","journal-title":"Annu Rev Immunol"},{"key":"1150_CR15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nri2273","volume":"8","author":"HJ Gould","year":"2008","unstructured":"Gould HJ, Sutton BJ (2008) IgE in allergy and asthma today. Nat Rev Immunol 8:205\u2013217","journal-title":"Nat Rev Immunol"},{"key":"1150_CR16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.pt.2005.02.010","volume":"21","author":"N Watanabe","year":"2005","unstructured":"Watanabe N, Bruschi F, Korenaga M (2005) IgE: a question of protective immunity in Trichinella spiralis infection. Trends Parasitol 21:175\u2013178","journal-title":"Trends Parasitol"},{"key":"1150_CR17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1398-9995.2007.01601.x","volume":"63","author":"PJ Cooper","year":"2008","unstructured":"Cooper PJ, Ayre G, Martin C, Rizzo JA, Ponte EV, Cruz AA (2008) Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment. Allergy 63:409\u2013417","journal-title":"Allergy"},{"key":"1150_CR18","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-60761-451-7","volume-title":"Cancer and IgE: Introducing the Concept of AllergoOncology","author":"ML Penichet","year":"2010","unstructured":"Penichet ML, Jensen-Jarolim E (2010) Cancer and IgE: Introducing the Concept of AllergoOncology. Springer, New York"},{"key":"1150_CR19","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1146\/annurev.iy.08.040190.003203","volume":"8","author":"DH Conrad","year":"1990","unstructured":"Conrad DH (1990) Fc epsilon RII\/CD23: the low affinity receptor for IgE. Annu Rev Immunol 8:623\u2013645","journal-title":"Annu Rev Immunol"},{"key":"1150_CR20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1146\/annurev.immunol.23.021704.115723","volume":"23","author":"RA Manz","year":"2005","unstructured":"Manz RA, Hauser AE, Hiepe F, Radbruch A (2005) Maintenance of serum antibody levels. Annu Rev Immunol 23:367\u2013386","journal-title":"Annu Rev Immunol"},{"key":"1150_CR21","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<748::AID-IJC14>3.0.CO;2-6","volume":"81","author":"WZ Wei","year":"1999","unstructured":"Wei WZ, Shi WP, Galy A, Lichlyter D, Hernandez S, Groner B, Heilbrun L, Jones RF (1999) Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 81:748\u2013754","journal-title":"Int J Cancer"},{"key":"1150_CR22","doi-asserted-by":"crossref","first-page":"22079","DOI":"10.1016\/S0021-9258(18)45670-0","volume":"265","author":"J Hakimi","year":"1990","unstructured":"Hakimi J, Seals C, Kondas JA, Pettine L, Danho W, Kochan J (1990) The alpha subunit of the human IgE receptor (FcERI) is sufficient for high affinity IgE binding. J Biol Chem 265:22079\u201322081","journal-title":"J Biol Chem"},{"key":"1150_CR23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4049\/jimmunol.157.1.221","volume":"157","author":"TW Wiegand","year":"1996","unstructured":"Wiegand TW, Williams PB, Dreskin SC, Jouvin MH, Kinet JP, Tasset D (1996) High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I. J Immunol 157:221\u2013230","journal-title":"J Immunol"},{"key":"1150_CR24","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1006\/jmbi.1996.0598","volume":"263","author":"R Schier","year":"1996","unstructured":"Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks JD (1996) Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 263:551\u2013567","journal-title":"J Mol Biol"},{"key":"1150_CR25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/1380-2933(95)00007-0","volume":"1","author":"R Schier","year":"1995","unstructured":"Schier R, Marks JD, Wolf EJ, Apell G, Wong C, McCartney JE, Bookman MA, Huston JS, Houston LL, Weiner LM, Adams GP (1995) In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1:73\u201381","journal-title":"Immunotechnology"},{"key":"1150_CR26","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1074\/jbc.271.7.3428","volume":"271","author":"JB Lyczak","year":"1996","unstructured":"Lyczak JB, Zhang K, Saxon A, Morrison SL (1996) Expression of novel secreted isoforms of human immunoglobulin E proteins. J Biol Chem 271:3428\u20133436","journal-title":"J Biol Chem"},{"key":"1150_CR27","first-page":"347","volume":"109","author":"G Helguera","year":"2005","unstructured":"Helguera G, Penichet ML (2005) Antibody-cytokine fusion proteins for the therapy of cancer. Methods Mol Med 109:347\u2013374","journal-title":"Methods Mol Med"},{"key":"1150_CR28","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1124\/jpet.105.095513","volume":"316","author":"TH Huang","year":"2006","unstructured":"Huang TH, Morrison SL (2006) A trimeric anti-HER2\/neu ScFv and tumor necrosis factor-alpha fusion protein induces HER2\/neu signaling and facilitates repair of injured epithelia. J Pharmacol Exp Ther 316:983\u2013991","journal-title":"J Pharmacol Exp Ther"},{"key":"1150_CR29","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0264-410X(02)00741-7","volume":"21","author":"JS Dela Cruz","year":"2003","unstructured":"Dela Cruz JS, Lau SY, Ramirez EM, De Giovanni C, Forni G, Morrison SL, Penichet ML (2003) Protein vaccination with the HER2\/neu extracellular domain plus anti-HER2\/neu antibody-cytokine fusion proteins induces a protective anti-HER2\/neu immune response in mice. Vaccine 21:1317\u20131326","journal-title":"Vaccine"},{"key":"1150_CR30","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1074-7613(00)80556-7","volume":"8","author":"D Dombrowicz","year":"1998","unstructured":"Dombrowicz D, Lin S, Flamand V, Brini AT, Koller BH, Kinet JP (1998) Allergy-associated FcRbeta is a molecular amplifier of IgE- and IgG-mediated in vivo responses. Immunity 8:517\u2013529","journal-title":"Immunity"},{"key":"1150_CR31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1084\/jem.183.1.49","volume":"183","author":"WP Fung-Leung","year":"1996","unstructured":"Fung-Leung WP, De Sousa-Hitzler J, Ishaque A, Zhou L, Pang J, Ngo K, Panakos JA, Chourmouzis E, Liu FT, Lau CY (1996) Transgenic mice expressing the human high-affinity immunoglobulin (Ig) E receptor alpha chain respond to human IgE in mast cell degranulation and in allergic reactions. J Exp Med 183:49\u201356","journal-title":"J Exp Med"},{"key":"1150_CR32","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.4049\/jimmunol.157.4.1645","volume":"157","author":"D Dombrowicz","year":"1996","unstructured":"Dombrowicz D, Brini AT, Flamand V, Hicks E, Snouwaert JN, Kinet JP, Koller BH (1996) Anaphylaxis mediated through a humanized high affinity IgE receptor. J Immunol 157:1645\u20131651","journal-title":"J Immunol"},{"key":"1150_CR33","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.1073\/pnas.86.19.7566","volume":"86","author":"B Bettler","year":"1989","unstructured":"Bettler B, Hofstetter H, Rao M, Yokoyama WM, Kilchherr F, Conrad DH (1989) Molecular structure and expression of the murine lymphocyte low-affinity receptor for IgE (Fc epsilon RII). Proc Natl Acad Sci USA 86:7566\u20137570","journal-title":"Proc Natl Acad Sci USA"},{"key":"1150_CR34","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nm0502-518","volume":"8","author":"D Zhu","year":"2002","unstructured":"Zhu D, Kepley CL, Zhang M, Zhang K, Saxon A (2002) A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat Med 8:518\u2013521","journal-title":"Nat Med"},{"key":"1150_CR35","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00262-008-0607-1","volume":"58","author":"P Karagiannis","year":"2009","unstructured":"Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, Knittelfelder R, Daniels TR, Hobson PS, Beavil AJ, Spicer J, Nestle FO, Penichet ML, Gould HJ, Jensen-Jarolim E, Karagiannis SN (2009) Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2\/neu-positive tumour cells. Cancer Immunol Immunother 58:915\u2013930","journal-title":"Cancer Immunol Immunother"},{"key":"1150_CR36","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1093\/emboj\/19.17.4632","volume":"19","author":"KM Ferguson","year":"2000","unstructured":"Ferguson KM, Darling PJ, Mohan MJ, Macatee TL, Lemmon MA (2000) Extracellular domains drive homo- but not hetero-dimerization of erbB receptors. EMBO J 19:4632\u20134643","journal-title":"EMBO J"},{"key":"1150_CR37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1172\/JCI0215640","volume":"110","author":"K Rafiq","year":"2002","unstructured":"Rafiq K, Bergtold A, Clynes R (2002) Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 110:71\u201379","journal-title":"J Clin Invest"},{"key":"1150_CR38","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/14058","volume":"1","author":"A Rodriguez","year":"1999","unstructured":"Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S (1999) Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1:362\u2013368","journal-title":"Nat Cell Biol"},{"key":"1150_CR39","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.4049\/jimmunol.150.8.3643","volume":"150","author":"FL Heijden van der","year":"1993","unstructured":"van der Heijden FL, Joost van Neerven RJ, van Katwijk M, Bos JD, Kapsenberg ML (1993) Serum-IgE-facilitated allergen presentation in atopic disease. J Immunol 150:3643\u20133650","journal-title":"J Immunol"},{"key":"1150_CR40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-1-4757-9966-8_29","volume":"417","author":"D Maurer","year":"1997","unstructured":"Maurer D, Ebner C, Reininger B, Petzelbauer P, Fiebiger E, Stingl G (1997) Mechanisms of Fc epsilon RI-IgE-facilitated allergen presentation by dendritic cells. Adv Exp Med Biol 417:175\u2013178","journal-title":"Adv Exp Med Biol"},{"key":"1150_CR41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0022-3565(25)33056-9","volume":"221","author":"BM Weichman","year":"1982","unstructured":"Weichman BM, Hostelley LS, Bostick SP, Muccitelli RM, Krell RD, Gleason JG (1982) Regulation of the synthesis and release of slow-reacting substance of anaphylaxis from sensitized monkey lung. J Pharmacol Exp Ther 221:295\u2013302","journal-title":"J Pharmacol Exp Ther"},{"key":"1150_CR42","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00262-005-0058-x","volume":"55","author":"CW Adams","year":"2006","unstructured":"Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX (2006) Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55:717\u2013727","journal-title":"Cancer Immunol Immunother"},{"key":"1150_CR43","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1158\/1078-0432.CCR-10-0987","volume":"16","author":"JR Junutula","year":"2010","unstructured":"Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hiraragi H, Fuji RN, Tibbitts J, Vandlen R, Spencer SD, Scheller RH, Polakis P, Sliwkowski MX (2010) Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 16:4769\u20134778","journal-title":"Clin Cancer Res"},{"key":"1150_CR44","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","volume":"68","author":"GD Lewis Phillips","year":"2008","unstructured":"Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280\u20139290","journal-title":"Cancer Res"},{"key":"1150_CR45","first-page":"367","volume-title":"The humoral immune response. In Immunobiology: the immune system in health and disease","author":"CA Janeway","year":"2005","unstructured":"Janeway CA, Travers P, Walport M, Shlomchik M (2005) The humoral immune response. In Immunobiology: the immune system in health and disease. Garland Science Publishing, New York, pp 367\u2013406"},{"key":"1150_CR46","doi-asserted-by":"crossref","unstructured":"Helguera G, Daniels TR, Rodriguez JA., Penichet ML (2010) Monoclonal antibodies, Human engineered. In: Flickinger M (ed) Encyclopedia of industrial biotechnology: bioprocess, bioseparation, and cell technology. New York, John Wiley & Sons, Inc","DOI":"10.1002\/9780470054581.eib446"},{"key":"1150_CR47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF01741326","volume":"34","author":"E Nagy","year":"1991","unstructured":"Nagy E, Berczi I, Sehon AH (1991) Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virus. Cancer Immunol Immunother 34:63\u201369","journal-title":"Cancer Immunol Immunother"},{"key":"1150_CR48","first-page":"133","volume":"10","author":"MH Kershaw","year":"1998","unstructured":"Kershaw MH, Darcy PK, Trapani JA, MacGregor D, Smyth MJ (1998) Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth. Oncol Res 10:133\u2013142","journal-title":"Oncol Res"},{"key":"1150_CR49","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3527::AID-IMMU3527>3.0.CO;2-5","volume":"29","author":"HJ Gould","year":"1999","unstructured":"Gould HJ, Mackay GA, Karagiannis SN, O\u2019Toole CM, Marsh PJ, Daniel BE, Coney LR, Zurawski VR Jr, Joseph M, Capron M, Gilbert M, Murphy GF, Korngold R (1999) Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur J Immunol 29:3527\u20133537","journal-title":"Eur J Immunol"},{"key":"1150_CR50","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.4049\/jimmunol.179.5.2832","volume":"179","author":"SN Karagiannis","year":"2007","unstructured":"Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, Fear DJ, Thompson RG, East N, Burke F, Moore RJ, Dombrowicz DD, Balkwill FR, Gould HJ (2007) IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 179:2832\u20132843","journal-title":"J Immunol"},{"key":"1150_CR51","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/eji.200323185","volume":"33","author":"SN Karagiannis","year":"2003","unstructured":"Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR, Schwartz LB, Balkwill FR, Gould HJ (2003) Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol 33:1030\u20131040","journal-title":"Eur J Immunol"},{"key":"1150_CR52","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.4049\/jimmunol.179.5.2815","volume":"179","author":"Y Tang","year":"2007","unstructured":"Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM (2007) Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol 179:2815\u20132823","journal-title":"J Immunol"},{"key":"1150_CR53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-1759(01)00559-2","volume":"261","author":"EM Yoo","year":"2002","unstructured":"Yoo EM, Chintalacharuvu KR, Penichet ML, Morrison SL (2002) Myeloma expression systems. J Immunol Methods 261:1\u201320","journal-title":"J Immunol Methods"},{"key":"1150_CR54","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00262-007-0371-7","volume":"57","author":"SN Karagiannis","year":"2008","unstructured":"Karagiannis SN, Bracher MG, Beavil RL, Beavil AJ, Hunt J, McCloskey N, Thompson RG, East N, Burke F, Sutton BJ, Dombrowicz D, Balkwill FR, Gould HJ (2008) Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. Cancer Immunol Immunother 57:247\u2013263","journal-title":"Cancer Immunol Immunother"},{"key":"1150_CR55","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860\u2013867","journal-title":"Nature"},{"key":"1150_CR56","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1111\/j.1600-6143.2009.02755.x","volume":"9","author":"VC Vries de","year":"2009","unstructured":"de Vries VC, Wasiuk A, Bennett KA, Benson MJ, Elgueta R, Waldschmidt TJ, Noelle RJ (2009) Mast cell degranulation breaks peripheral tolerance. Am J Transplant 9:2270\u20132280","journal-title":"Am J Transplant"},{"key":"1150_CR57","doi-asserted-by":"crossref","unstructured":"Wasiuk A, de Vries VC, Nowak EC.,Noelle RJ (2010) Mast cells in allergy and tumor disease. In: Penichet ML, Jensen-Jarolim E (eds) Cancer and IgE: introducing the concept of AllergoOncology. New York, Springer, pp 137\u2013158","DOI":"10.1007\/978-1-60761-451-7_6"},{"key":"1150_CR58","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1200\/JCO.2008.16.8351","volume":"27","author":"S Lennon","year":"2009","unstructured":"Lennon S, Barton C, Banken L, Gianni L, Marty M, Baselga J, Leyland-Jones B (2009) Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol 27:1685\u20131693","journal-title":"J Clin Oncol"},{"key":"1150_CR59","first-page":"409","volume":"13","author":"A Garoufali","year":"2008","unstructured":"Garoufali A, Kyriakou F, Kountourakis P, Yioti I, Malliou S, Nikaki A, Kardara E, Frangos I, Koumna S, Baziotis N, Scorilas A, Ardavanis A (2008) Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer. J Buon 13:409\u2013413","journal-title":"J Buon"},{"key":"1150_CR60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000010155","volume":"48","author":"TH Cheung","year":"1999","unstructured":"Cheung TH, Wong YF, Chung TK, Maimonis P, Chang AM (1999) Clinical use of serum c-erbB-2 in patients with ovarian masses. Gynecol Obstet Invest 48:133\u2013137","journal-title":"Gynecol Obstet Invest"},{"key":"1150_CR61","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/BF01247465","volume":"120","author":"H Meden","year":"1994","unstructured":"Meden H, Marx D, Fattahi A, Rath W, Kron M, Wuttke W, Schauer A, Kuhn W (1994) Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy. J Cancer Res Clin Oncol 120:378\u2013381","journal-title":"J Cancer Res Clin Oncol"},{"key":"1150_CR62","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1365-2354.2009.01112.x","volume":"19","author":"M Hoopmann","year":"2010","unstructured":"Hoopmann M, Sachse K, Valter MM, Becker M, Neumann R, Ortmann M, Gohring UJ, Thomas A, Mallmann P, Schondorf T (2010) Serological and immunohistochemical HER-2\/neu statuses do not correlate and lack prognostic value for ovarian cancer patients. Eur J Cancer Care (Engl) 19:809\u2013815","journal-title":"Eur J Cancer Care (Engl)"},{"key":"1150_CR63","first-page":"232","volume":"1785","author":"JM Lafky","year":"2008","unstructured":"Lafky JM, Wilken JA, Baron AT, Maihle NJ (2008) Clinical implications of the ErbB\/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 1785:232\u2013265","journal-title":"Biochim Biophys Acta"},{"key":"1150_CR64","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2008.17.8400","volume":"27","author":"J Berek","year":"2009","unstructured":"Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF (2009) Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 27:418\u2013425","journal-title":"J Clin Oncol"},{"key":"1150_CR65","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1200\/JCO.2004.11.035","volume":"22","author":"DM King","year":"2004","unstructured":"King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim K, Eickhoff J, Kendra K, Reisfeld R, Gillies SD, Sondel P (2004) Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol 22:4463\u20134473","journal-title":"J Clin Oncol"},{"key":"1150_CR66","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CJI.0b013e31818b3dad","volume":"32","author":"P Braly","year":"2009","unstructured":"Braly P, Nicodemus CF, Chu C, Collins Y, Edwards R, Gordon A, McGuire W, Schoonmaker C, Whiteside T, Smith LM, Method M (2009) The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother 32:54\u201365","journal-title":"J Immunother"},{"key":"1150_CR67","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.4049\/jimmunol.0900842","volume":"183","author":"EA Nigro","year":"2009","unstructured":"Nigro EA, Brini AT, Soprana E, Ambrosi A, Dombrowicz D, Siccardi AG, Vangelista L (2009) Antitumor IgE adjuvanticity: key role of Fc epsilon RI. J Immunol 183:4530\u20134536","journal-title":"J Immunol"},{"key":"1150_CR68","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.4049\/jimmunol.156.9.3151","volume":"156","author":"ML Disis","year":"1996","unstructured":"Disis ML, Gralow JR, Bernhard H, Hand SL, Rubin WD, Cheever MA (1996) Peptide-based, but not whole protein, vaccines elicit immunity to HER-2\/neu, oncogenic self-protein. J Immunol 156:3151\u20133158","journal-title":"J Immunol"},{"key":"1150_CR69","first-page":"343","volume":"86","author":"R Bheekha Escura","year":"1995","unstructured":"Bheekha Escura R, Wasserbauer E, Hammerschmid F, Pearce A, Kidd P, Mudde GC (1995) Regulation and targeting of T-cell immune responses by IgE and IgG antibodies. Immunology 86:343\u2013350","journal-title":"Immunology"},{"key":"1150_CR70","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2172-11-34","volume":"11","author":"J Gong","year":"2010","unstructured":"Gong J, Yang NS, Croft M, Weng IC, Sun L, Liu FT, Chen SS (2010) The antigen presentation function of bone marrow-derived mast cells is spatiotemporally restricted to a subset expressing high levels of cell surface FcepsilonRI and MHC II. BMC Immunol 11:34","journal-title":"BMC Immunol"},{"key":"1150_CR71","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/ni.1737","volume":"10","author":"T Yoshimoto","year":"2009","unstructured":"Yoshimoto T, Yasuda K, Tanaka H, Nakahira M, Imai Y, Fujimori Y, Nakanishi K (2009) Basophils contribute to T(H)2-IgE responses in vivo via IL-4 production and presentation of peptide-MHC class II complexes to CD4+ T cells. Nat Immunol 10:706\u2013712","journal-title":"Nat Immunol"},{"key":"1150_CR72","first-page":"1305","volume":"8","author":"H Satoh","year":"2001","unstructured":"Satoh H, Ishikawa H, Yamashita YT, Kurishima K, Ohtsuka M, Sekizawa K (2001) Peritoneal carcinomatosis in lung cancer patients. Oncol Rep 8:1305\u20131307","journal-title":"Oncol Rep"},{"key":"1150_CR73","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1148\/rg.233025712","volume":"23","author":"AE Hanbidge","year":"2003","unstructured":"Hanbidge AE, Lynch D, Wilson SR (2003) US of the peritoneum. Radiographics 23:663\u2013684 discussion 684\u2013665","journal-title":"Radiographics"},{"key":"1150_CR74","unstructured":"Ozols RF, Schwartz PE, Eifel PJ (2001) Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Philadelphia, PA, Lippincott Williams & Wilkins, pp 1597\u20131632"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-011-1150-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-011-1150-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-011-1150-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T16:24:02Z","timestamp":1741969442000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-011-1150-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,30]]},"references-count":74,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["1150"],"URL":"https:\/\/doi.org\/10.1007\/s00262-011-1150-z","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,30]]}}}